Andrei Gafita1, Isabel Rauscher2, Margitta Retz3, Karina Knorr2, Matthias Heck3, Hans-Jürgen Wester4, Calogero D'Alessandria2, Wolfgang A Weber2, Matthias Eiber2, Robert Tauber3. 1. Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany andrei.gafita@tum.de. 2. Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University Munich, Munich, Germany. 3. Department of Urology, Klinikum rechts der Isar, Technical University Munich, Munich, Germany; and. 4. Chair of Pharmaceutical Radiochemistry, Technical University of Munich, Munich, Germany.
Abstract
Our aim was to retrospectively evaluate the feasibility of rechallenge 177Lu-prostate-specific membrane antigen (177Lu-PSMA) radioligand therapy. Methods: Rechallenge radioligand therapy was defined as subsequent treatment with 177Lu-PSMA after initial exposure with an excellent response followed by progression. Biochemical, radiographic, clinical antitumor response, and adverse events were analyzed. Prostate-specific antigen (PSA) progression-free survival (PFS) and overall survival were calculated. Results: Eight patients underwent a median of 2 (range: 1-4) cycles of rechallenge with 177Lu-PSMA for imaging and therapy. A maximum PSA decrease of 50% was achieved in 3 patients (37.5%). Radiographic response was favorable in 3 patients, whereas 4 exhibited progressive disease. Eastern Cooperative Oncology Group performance status was stable during therapy in all patients. No grade 4 toxicity was noticed, and grade 3 toxicity occurred in 3 patients (37.5%). The median PSA-PFS and overall survival were 3.2 mo (95% confidence interval, 2.6-3.7 mo) and 14.0 mo (95% confidence interval, 6.2-21.8 mo), respectively. Conclusion: In a small patient cohort with an initial excellent response, 177Lu-PSMA rechallenge is still active, with lower efficacy and higher toxicity.
Our aim was to retrospectively evaluate the feasibility of rechallenge 177Lu-prostate-specific membrane antigen (177Lu-PSMA) radioligand therapy. Methods: Rechallenge radioligand therapy was defined as subsequent treatment with 177Lu-PSMA after initial exposure with an excellent response followed by progression. Biochemical, radiographic, clinical antitumor response, and adverse events were analyzed. Prostate-specific antigen (PSA) progression-free survival (PFS) and overall survival were calculated. Results: Eight patients underwent a median of 2 (range: 1-4) cycles of rechallenge with 177Lu-PSMA for imaging and therapy. A maximum PSA decrease of 50% was achieved in 3 patients (37.5%). Radiographic response was favorable in 3 patients, whereas 4 exhibited progressive disease. Eastern Cooperative Oncology Group performance status was stable during therapy in all patients. No grade 4 toxicity was noticed, and grade 3 toxicity occurred in 3 patients (37.5%). The median PSA-PFS and overall survival were 3.2 mo (95% confidence interval, 2.6-3.7 mo) and 14.0 mo (95% confidence interval, 6.2-21.8 mo), respectively. Conclusion: In a small patient cohort with an initial excellent response, 177Lu-PSMA rechallenge is still active, with lower efficacy and higher toxicity.
Authors: Mesude Bicak; Katharina Lückerath; Teja Kalidindi; Michael E Phelps; Sven-Erik Strand; Michael J Morris; Caius G Radu; Robert Damoiseaux; Mari T Peltola; Norbert Peekhaus; Austin Ho; Darren Veach; Ann-Christin Malmborg Hager; Steven M Larson; Hans Lilja; Michael R McDevitt; Robert J Klein; David Ulmert Journal: Proc Natl Acad Sci U S A Date: 2020-06-12 Impact factor: 11.205
Authors: Johanna Maffey-Steffan; Lorenza Scarpa; Anna Svirydenka; Bernhard Nilica; Christian Mair; Sabine Buxbaum; Jasmin Bektic; Elisabeth von Guggenberg; Christian Uprimny; Wolfgang Horninger; Irene Virgolini Journal: Eur J Nucl Med Mol Imaging Date: 2019-11-27 Impact factor: 9.236
Authors: Sazan Rasul; Tim Wollenweber; Lucia Zisser; Elisabeth Kretschmer-Chott; Bernhard Grubmüller; Gero Kramer; Shahrokh F Shariat; Harald Eidherr; Markus Mitterhauser; Chrysoula Vraka; Werner Langsteger; Marcus Hacker; Alexander R Haug Journal: Cancers (Basel) Date: 2021-05-20 Impact factor: 6.639
Authors: Andrei Gafita; Hui Wang; Andrew Robertson; Wesley R Armstrong; Raphael Zaum; Manuel Weber; Farid Yagubbayli; Clemens Kratochwil; Tristan R Grogan; Kathleen Nguyen; Fernando Navarro; Rouzbeh Esfandiari; Isabel Rauscher; Bjoern Menze; David Elashoff; Ebrahim S Delpassand; Ken Herrmann; Johannes Czernin; Michael S Hofman; Jeremie Calais; Wolfgang P Fendler; Matthias Eiber Journal: J Nucl Med Date: 2021-05-28 Impact factor: 11.082